Renal Biopsy in Nephrotic and Nephritic Syndrome
Kidney biopsy is the gold standard for diagnosing glomerular diseases presenting with nephrotic or nephritic syndrome, and should be performed when the result will modify treatment or provide essential prognostic information—with specific exceptions where serologic testing or clinical presentation allows empiric therapy. 1
Core Principle: When to Biopsy
Biopsy should be performed if the histologic diagnosis is expected to change management and/or provide prognostic information that cannot be obtained through non-invasive means. 1
The decision hinges on whether tissue diagnosis will alter your therapeutic approach or risk stratification. 1
Nephrotic Syndrome: Age-Stratified Approach
Children (Age 1–12 Years)
Do NOT biopsy at initial presentation if the child presents with typical features: edema, proteinuria ≥40 mg/h/m² (or first-morning UPCR ≥2 g/g), serum albumin ≤2.5 g/dL, and age 1–12 years. 2, 3
Minimal change disease accounts for 80–90% of cases in this age group, justifying empiric corticosteroid therapy (prednisone 60 mg/m²/day for 4 weeks, then 40 mg/m² on alternate days for 4 weeks). 4, 5
Biopsy IS indicated in children if any of the following are present:
- Steroid resistance after 8 weeks of adequate corticosteroid therapy (no complete or partial remission) 2, 3
- Age <1 year or ≥12 years at presentation 2, 3
- Persistent gross hematuria at diagnosis 2
- Renal insufficiency (elevated creatinine or reduced eGFR) 2
- Nephritis at presentation (combination of reduced eGFR, hematuria, and hypertension)—this has 98% specificity for FSGS 4
The combination of steroid resistance after 6 weeks AND/OR nephritis at diagnosis yields optimal sensitivity (80%) and specificity (75%) for predicting FSGS, making these the strongest biopsy triggers. 4
Adolescents (≥12 Years) and Adults
Biopsy is recommended for all adolescents ≥12 years and adults with new-onset nephrotic syndrome to establish the specific histologic diagnosis. 2, 6
Exception—biopsy may be deferred in the following scenarios where serologic testing provides diagnosis:
- PLA2R antibody-positive membranous nephropathy, especially with normal eGFR 1, 2
- MPO+ or PR3+ ANCA vasculitis with compatible clinical presentation (though biopsy still provides prognostic information and should be performed for confirmation) 1, 6
- Anti-GBM disease with positive anti-GBM antibodies 1
- Fabry disease with confirmed enzymatic or genetic diagnosis 1
- Familial FSGS in families with well-characterized mutations 1
- Systemic lupus erythematosus with typical serologies (though biopsy is often still performed to guide treatment intensity) 1
In adults, the differential diagnosis is broad—membranous nephropathy, FSGS (primary, genetic, secondary, or undetermined), minimal change disease, and secondary causes (diabetes, amyloidosis, paraprotein-related disease)—making histologic confirmation essential for targeted therapy. 2
Nephritic Syndrome: Biopsy Indications
Core Indications
Biopsy should be performed in patients presenting with nephritic features: glomerular hematuria (>80% dysmorphic RBCs or red-cell casts), proteinuria (often sub-nephrotic but may be nephrotic-range), reduced eGFR, and hypertension. 6, 7
IgA nephropathy is the single most common diagnosis in nephritic syndrome globally (approximately 38% of cases), followed by lupus nephritis (8%) and Henoch-Schönlein purpura (7%). 7
Rapidly progressive glomerulonephritis (RPGN) with rising creatinine and active urinary sediment is an urgent indication for biopsy, as histology determines whether to use pulse steroids alone versus steroids plus cyclophosphamide. 6, 8
When Biopsy May Be Deferred in Nephritic Syndrome
MPO+ or PR3+ ANCA vasculitis with compatible clinical presentation may be treated empirically with immunosuppression, though biopsy should still be performed when feasible to confirm diagnosis and assess chronicity (glomerular sclerosis, crescents, tubulointerstitial fibrosis). 1, 6
Anti-GBM disease with positive anti-GBM antibodies and pulmonary hemorrhage may be treated immediately, but biopsy remains valuable for prognosis (extent of crescents predicts renal recovery). 1
Technical Requirements for Adequate Biopsy
The specimen must contain at least 8–10 glomeruli for light microscopy to reliably diagnose or exclude specific histopathologic patterns. 1, 6
Three complementary modalities are mandatory:
- Light microscopy with PAS, H&E, trichrome, and Jones' silver stains 1
- Immunofluorescence or immunohistochemistry for IgG, IgA, IgM, C3, C4, C1q, fibrin, κ and λ light chains 1
- Electron microscopy to define location and characteristics of immune deposits, extent of foot-process effacement, and structural GBM alterations 1
For focal and segmental lesions (e.g., FSGS), more tissue may be needed to capture diagnostic areas. 1
Timing of Biopsy
Perform biopsy within the first month after nephrotic or nephritic syndrome onset, preferably before starting immunosuppressive therapy, to avoid obscuring histologic changes. 2
In ANCA vasculitis or anti-GBM disease with life-threatening manifestations, start immunosuppression immediately but still pursue biopsy for confirmation and prognostic assessment. 6
Safety Considerations and Contraindications
Exclude coagulopathy before percutaneous biopsy; correct INR, platelet count, and discontinue antiplatelet agents. 9, 10
Control blood pressure to normotensive range (<140/90 mmHg, ideally ≤125/75 mmHg) before biopsy to minimize bleeding risk. 9, 10
Assess kidney size and echogenicity with ultrasound; kidneys <9 cm in length or with markedly increased echogenicity (advanced chronicity) have lower diagnostic yield and higher risk. 6
If percutaneous biopsy is contraindicated (uncorrectable coagulopathy, single kidney, uncontrolled hypertension), consider transjugular renal biopsy via the internal jugular vein. 6, 9, 10
Major bleeding occurs in approximately 4% of biopsies and can usually be managed with selective arterial embolization. 6, 9
Common Pitfalls to Avoid
Do not delay biopsy in steroid-resistant nephrotic syndrome beyond 8 weeks of adequate corticosteroid therapy in children, as early histologic diagnosis enables timely initiation of second-line therapy (calcineurin inhibitors, rituximab). 2, 3
Do not assume all proteinuria in diabetic patients is diabetic nephropathy—atypical features (rapid onset, active urinary sediment, absence of retinopathy, short diabetes duration) warrant biopsy to exclude superimposed glomerular disease. 6, 8
Do not withhold biopsy in elderly patients based on age alone; the indications and risks are similar to younger adults, and many glomerular diseases (membranous nephropathy, ANCA vasculitis, monoclonal gammopathy of renal significance) peak in older age. 6
Do not perform biopsy in children age 1–12 years with typical steroid-sensitive nephrotic syndrome at initial presentation, as this exposes the child to unnecessary risk without changing management. 2, 3, 5
**In congenital nephrotic syndrome (onset <1 year), perform genetic testing first** rather than biopsy, as genetic mutations are identified in >85% of cases and biopsy rarely changes management unless eGFR <30 mL/min/1.73 m² and rare diagnoses (congenital membranous nephropathy) are suspected. 6